Healthcare / Medical Instruments & SuppliesTokyo
$907.00
-7.00 (-0.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $356.7M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
17.1x
↓EV/EBITDA
12.2x
↓ROE
2.1%
↑Gross Margin
29.7%
↓Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-3.2%
FCF CAGR
—
FCF margin
5.7%
FCF / Net income
5.53x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.39B · net income $65.7M · FCF $363.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.39B | $6.39B | $6.31B | $6.38B | $7.04B |
| Net Income | $65.7M | $65.7M | $222.4M | $263.6M | $305.9M |
| EBITDA | $267.2M | $267.2M | $398.0M | $446.9M | $429.1M |
| EPS | 18.52 | 18.52 | 62.85 | 74.64 | — |
| Gross Margin | 29.7% | 29.7% | 28.5% | 34.0% | 40.6% |
| Operating Margin | 0.6% | 0.6% | -1.7% | 1.6% | 10.3% |
| Net Margin | 1.0% | 1.0% | 3.5% | 4.1% | 4.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.66 | 0.66 | 0.72 | 0.80 | 0.79 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $363.1M | $363.1M | $356.7M | $-288.1M | $-34.0M |
| Returns | |||||
| ROE | 2.1% | 2.1% | 7.1% | 8.9% | 11.1% |
| Valuation | |||||
| P/E | 17.14 | 17.14 | 10.56 | 10.92 | — |
| EV/EBITDA | 12.20 | 12.20 | 6.55 | 8.48 | 14.76 |
| P/B | 1.01 | 1.01 | 0.75 | 0.97 | 2.08 |
| Growth & Yield | |||||
| Revenue Growth | 1.2% | 1.2% | -1.0% | -9.4% | — |
| EPS Growth | -70.5% | -70.5% | -15.8% | — | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
63.2%
EPS terminal req.
$80.48
Spread vs growth
-133.7%
5Y implied EPS CAGR
39.4%
EPS terminal req.
$97.38
Spread vs growth
-109.9%
10Y implied EPS CAGR
23.8%
EPS terminal req.
$156.83
Spread vs growth
-94.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.5%
Start / end P/E
11.8x → 49.0x
EPS bridge
62.85 → 18.52
Residual
-221.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.